SCHEMBL358758

SCHEMBL358758

CNC(=O)CC[C@H](N)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.58
GRM8 O00222 1/20 0.58
GRM6 O15303 1/20 0.58
GRIN2D O15399 1/20 0.58
GRIN3B O60391 1/20 0.58
CYP1A2 P05177 1/20 0.58
GRIK1 P39086 1/20 0.58
GRM5 P41594 1/20 0.58
GRIA1 P42261 1/20 0.58
GRIA2 P42262 1/20 0.58
GRIA3 P42263 1/20 0.58
SLC1A3 P43003 1/20 0.58
SLC1A2 P43004 1/20 0.58
SLC1A1 P43005 1/20 0.58
GRIA4 P48058 1/20 0.58
GRIN1 Q05586 1/20 0.58
GRIN2A Q12879 1/20 0.58
GRIK2 Q13002 1/20 0.58
GRIK3 Q13003 1/20 0.58
GRIN2B Q13224 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL154380 1.00 GSR (0.58) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL8138 1.00 GSR (0.58) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL8587639 0.92 PMP22 (0.52) GSRGRM8GRM6GRIN2DGRIN3B
Phosphoric Acid SCHEMBL8519189 0.92 GRM8 (0.50) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL14423586 0.88 GSR (0.50) GSRGRM8GRM6GRIN2DGRIN3B
Lysine SCHEMBL4561856 0.88 GSR (0.67) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL19774715 0.87 SLC1A1 (0.48) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL22186668 0.85 GRM8 (0.56) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL5198612 0.83 GRM8 (0.54) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL1769601 0.83 OTC (0.45) GSRGRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720087-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2026-04-08 EP claimed
CN-115927217-B Gamma-glutamylmethylamine synthetase mutant and application thereof 河北远大九孚生物科技有限公司 2025-02-18 CN claimed
WO-2024246269-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR ZEALAND PHARMA A/S (DK) 2024-12-05 WO claimed
US-20240301023-A1 PEPTIDES AND USES THEREOF PreveCeutical Medical Inc. (CA) 2024-09-12 US claimed
CN-118261890-A Transformer substation fault detection method based on Gamma-WMA FILTER technology 国网甘肃省电力公司甘南供电公司 2024-06-28 CN claimed
US-20240067696-A1 GLUCAGON ANALOGUES ZEALAND PHARMA A/S (DK) 2024-02-29 US claimed
EP-4295866-A2 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Virometix AG (CH) 2023-12-27 EP claimed
EP-3638284-B1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIROMETIX AG (CH) 2023-08-30 EP claimed
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIROMETIX AG (CH) 2023-06-20 US claimed
EP-4175970-A1 PEPTIDES AND USES THEREOF Preveceutical Medical Inc. (CA) 2023-05-10 EP claimed
WO-2022000043-A1 PEPTIDES AND USES THEREOF PreveCeutical Medical Inc. (CA) 2022-01-06 WO claimed
US-20210101941-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Universität Zürich (CH) 2021-04-08 US claimed
EP-3638284-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS Virometix AG (CH) 2020-04-22 EP claimed
WO-2018229156-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS VIROMETIX AG (CH) 2018-12-20 WO claimed
US-9101662-B2 Compositions with modulating agents FOAMIX PHARMACEUTICALS LTD. (IL) 2015-08-11 US claimed
EP-2462147-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2014-11-12 EP claimed
US-8795693-B2 Compositions with modulating agents FOAMIX LTD. (IL) 2014-08-05 US claimed
EP-2097065-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS Foamix Ltd. (IL) 2009-09-09 EP claimed
WO-2008152444-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS FOAMIX LTD. (US) 2008-12-18 WO claimed
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions FOAMIX LTD. (IL) 2008-08-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240301023-A1 PEPTIDES AND USES THEREOF OPRL1, OPRK1, OPRM1 GSR 4241/4885GRM8 466/4885GRM6 339/4885
US-11680085-B2 Cyclic peptides for protection against respiratory syncytial virus VIP, LNPEP, CSTB GSR 1013/4885GRM8 3493/4885GRM6 4190/4885
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions CUTA, SLTM, SMO GSR 355/4885GRM8 2310/4885GRM6 2292/4885
US-20210101941-A1 CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS QPCT, QPCTL, VIP GSR 1643/4885GRM8 1035/4885GRM6 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.